Amarin’s Vascepa and Allergan’s migraine project ubrogepant are the high-profile pending FDA approval decisions as the sector heads into the last month of the year.
Hopes for lumateperone rest on schizophrenia as bipolar data raise questions.
Intra-Cellular looks to shore up lumateperone, while Myovant wants to take on Abbvie on its own turf.
A look at the biggest potential drug launches this year reveals a long list of blockbusters from the likes of Alexion and Abbvie. But what impact will the shutdown have?
Ionis seeks a green light for Waylivra in a rare disease, but safety concerns could seriously hit sales. Meanwhile, Intra-Cellular needs a pivotal bipolar trial win for…